Arnold Library

Development of Modified Vaccinia Ankara-5T4 as Specific Immunotherapy for Advanced Human Cancer.

Tykodi, Scott S. and Thompson, John A. (2008) Development of Modified Vaccinia Ankara-5T4 as Specific Immunotherapy for Advanced Human Cancer. Expert Opinion on Biological Therapy, 8 (12). pp. 1947-1953. ISSN 1471-2598

[img] Text (Complete manuscript)
ThompsonManuscript_10_23_08.pdf
Restricted to Repository staff only
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (144Kb) | Request a copy
Article URL: http://www.informapharmascience.com/doi/abs/10.151...

Abstract

Background: The tumor-associated antigen 5T4 is expressed on a high percentage of human carcinomas and has limited expression in normal tissues. A recombinant pox virus vector expressing this antigen, modified vaccinia Ankara (MVA)-5T4, has been tested as a cancer vaccine. Objective: Treatment with MVA-5T4 has been studied both as a single agent and in combination with standard chemo-, biologic-, or targeted-therapies in patients with advanced colorectal cancer, renal cell carcinoma (RCC), or hormone-refractory prostate cancer. Methods: This review summarizes data from clinical studies with MVA-5T4 reported in published manuscripts, meeting abstracts, or posted on websites relevant to clinical trials or MVA-5T4. Results/conclusion: Vaccination with MVA-5T4 is well tolerated and elicits 5T4-specific humoral and/or cellular responses in the majority of treated patients. Retrospective analyses of phase II studies have suggested a positive association between immune responses to 5T4 and favorable clinical outcomes. An ongoing phase III, double-blind, placebo-controlled trial seeks to confirm a positive association between vaccination with MVA-5T4 and survival in patients with advanced RCC.

Item Type: Article
Additional Information: This is an electronic version of an article published in Expert Opinion in Biological Therapy, December 2008, Vol. 8, No. 12, Pages 1947-1953. Expert Opinion in Biological Therapy is available online at: www.informapharmascience.com
DOI: 10.1517/14712590802567298
PubMed ID: 18990081
NIHMSID: NIHMS75640
PMCID: PMC2592504
Grant Numbers: K08 CA121912-03
Keywords or MeSH Headings: Antibody Formation; Cancer Vaccines/immunology/*therapeutic use; Clinical Trials as Topic; Humans; Immunity, Cellular; Neoplasms/*therapy
Subjects: Cellular and Organismal Processes > Immune Response > Cellular immunity
Therapeutics > Biological Therapy > Vaccines
Diseases > Solid tumors
Depositing User: authors@FHCRC Administrator-Import
Date Deposited: 23 Oct 2008 21:58
Last Modified: 14 Feb 2012 14:42
URI: http://authors.fhcrc.org/id/eprint/30

Repository Administrators Only

View Item View Item
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024
Seattle, WA 98109

a 501(c)(3) nonprofit organization.

© Terms of Use & Privacy Policy